Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | GALR1 | P47211 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065756 | 0.92 | HTR2C (0.53) | HTR2CASIC3GALR1KDM1ATSHR | |
| SCHEMBL8689815 | 0.83 | HTR2C (0.62) | HTR2CASIC3KDM1AIDO1PARP10 | |
| SCHEMBL1263144 | 0.80 | TSHR (0.58) | HTR2CASIC3KDM1ATSHRMAPK1 | |
| SCHEMBL29678302 | 0.80 | TSHR (0.58) | HTR2CASIC3KDM1ATSHRMAPK1 | |
| SCHEMBL15561965 | 0.79 | RXRA (0.38) | HTR2CKDM1AIDO1 | |
| Ammonia Solution, Strong SCHEMBL20472961 | 0.78 | MAOB (0.56) | HTR2CASIC3KDM1ATSHRMAPK1 | |
| SCHEMBL31678636 | 0.78 | HTR2C (0.49) | HTR2CASIC3GALR1NOTUMPARP10 | |
| SCHEMBL14893807 | 0.77 | KDM1A (0.49) | HTR2CASIC3GALR1KDM1ATSHR | |
| SCHEMBL12348391 | 0.77 | HTR2C (0.59) | HTR2CASIC3GALR1KDM1ATSHR | |
| SCHEMBL8349987 | 0.77 | ASIC3 (0.64) | HTR2CASIC3KDM1AIDO1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2887802-A2 | METHODS OF SOIL PEST CONTROL | Syngenta Participations AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029707-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029706-A2 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029710-A2 | METHODS OF SOIL PEST CONTROL | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029708-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014019609-A1 | METHODS OF PEST CONTROL IN SOYBEAN | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-06 | — | — | WO | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | HTR2C 917/4885ASIC3 2141/4885GALR1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.